よむ、つかう、まなぶ。
参考資料3 有効性評価に基づく大腸がん検診ガイドライン2024年度版 (61 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_71872.html |
| 出典情報 | がん検診のあり方に関する検討会（第46回 3／23）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
18.
19.
20.
21.
22.
29.
24.
25.
follow-up. Gt. 201261(7が1086-40. doj: 10.1136/gutinl-2011-800774. PMTD:
22052062
Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, Dassonwle E,
Bonithon-Kopp C. Reduction in Colorectal Cancer Moytality by Fecal Occult
Blood Screening in a French Controlled Study. Gastroenterology
2004:126(7:1674-80. doi: 10.1053放gastro.2004.02.018. PMID: 15188160
Lindholm E, Brevinge H, Haghmd E. Suryivat benefit in a randomized clinnca]
trial of faecal occult blood screenng for colorectal cancer. Br J Surg.
2008:95(8):1029-36. doi: 10.1002/bjs.6136. PMID: 18563785
Kronborg 0, Jergensen OD, Fenger C, Rasmussen M. Randomnzed study of
biennial screening with a faecal occult blood test: results after nme screen1ng
rounds. Scand J Gastroenterol. 2004:39(9:846-51. doi:
10.1080/00365520410003182. PMID 15518882
Lu M, Luo X, Hi N, Chen H, Dai M. Diagnostic Accuracy Of Fecal Occult Blood
Tests For Detecting Proximal Versus Distal Colorecta] Neoplasia: A Systematic
Review And Meta-Analysis. Clin Epidemiol. 2019:11:943-54. do1:
10.21477CLEPS213677. PMID 831695506
Stegeman 1, van Doorn SC, Mundt MW, Mallant-Hent RC, Bongers EE, Elferink
MA, Fockens P Stroobants AK, Bossuyt PM, Dekker E. Participation, yield, and
interval carcinomas in three rounds of biennial FTT-based colorectal cancer
sereening. Cancer Epidemio1. 2015: 39(3): 388-98. doi:
10.1016/.canep.2015.03.012. PMTD: 25910865
Ross1 PG, Carretta BE, Mangone L, Baracco S, Serraino D, Zorg1 Mi Colorectal
Cancer Screening IMPATTO Working Group. Incidence of interval cancers 1n
faecal innumnochemical test colorectal screenimg programmes in Italy. J Med
Screen. 2018: 25(1): 82-9. doi: 10.117770969141816686391. PMID: 28195508
Zorgi ML Hassan C, Senore C, Capodaglio G, Turrin A, Narne E, MIussato A,
Rizzato S, Chinellato E, Zamberlan S, Repici A, Rugge M. Interval colorectal
cancers after negative faecal immunochemical test in a 18-year screen1ng
programme.J Med Screen. 2021: 28(②): 181-9. doi: 10.117770969141320918613.
PMID 32393153
Jensen CD, Corley DA, Quinn VP Douben CA, Zauber AG, Lee JK, 2hao WEK,
Marks AR, Schottinger JE, Ghai NR, Lee AT, Contreras R, Klabunde CN,
Quesenberry CP Levin TR, Mysliwiec PA. Fecal Immunochemnical Test Program
Performanmce Over 4 Rounds of Annual Screening: A Retrospective Cohort Study
Ann Intern Med. 2016: 164(⑦): 456-63. doi. 10.7326/M15-0983. PMID:26811150
61
19.
20.
21.
22.
29.
24.
25.
follow-up. Gt. 201261(7が1086-40. doj: 10.1136/gutinl-2011-800774. PMTD:
22052062
Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D, Dassonwle E,
Bonithon-Kopp C. Reduction in Colorectal Cancer Moytality by Fecal Occult
Blood Screening in a French Controlled Study. Gastroenterology
2004:126(7:1674-80. doi: 10.1053放gastro.2004.02.018. PMID: 15188160
Lindholm E, Brevinge H, Haghmd E. Suryivat benefit in a randomized clinnca]
trial of faecal occult blood screenng for colorectal cancer. Br J Surg.
2008:95(8):1029-36. doi: 10.1002/bjs.6136. PMID: 18563785
Kronborg 0, Jergensen OD, Fenger C, Rasmussen M. Randomnzed study of
biennial screening with a faecal occult blood test: results after nme screen1ng
rounds. Scand J Gastroenterol. 2004:39(9:846-51. doi:
10.1080/00365520410003182. PMID 15518882
Lu M, Luo X, Hi N, Chen H, Dai M. Diagnostic Accuracy Of Fecal Occult Blood
Tests For Detecting Proximal Versus Distal Colorecta] Neoplasia: A Systematic
Review And Meta-Analysis. Clin Epidemiol. 2019:11:943-54. do1:
10.21477CLEPS213677. PMID 831695506
Stegeman 1, van Doorn SC, Mundt MW, Mallant-Hent RC, Bongers EE, Elferink
MA, Fockens P Stroobants AK, Bossuyt PM, Dekker E. Participation, yield, and
interval carcinomas in three rounds of biennial FTT-based colorectal cancer
sereening. Cancer Epidemio1. 2015: 39(3): 388-98. doi:
10.1016/.canep.2015.03.012. PMTD: 25910865
Ross1 PG, Carretta BE, Mangone L, Baracco S, Serraino D, Zorg1 Mi Colorectal
Cancer Screening IMPATTO Working Group. Incidence of interval cancers 1n
faecal innumnochemical test colorectal screenimg programmes in Italy. J Med
Screen. 2018: 25(1): 82-9. doi: 10.117770969141816686391. PMID: 28195508
Zorgi ML Hassan C, Senore C, Capodaglio G, Turrin A, Narne E, MIussato A,
Rizzato S, Chinellato E, Zamberlan S, Repici A, Rugge M. Interval colorectal
cancers after negative faecal immunochemical test in a 18-year screen1ng
programme.J Med Screen. 2021: 28(②): 181-9. doi: 10.117770969141320918613.
PMID 32393153
Jensen CD, Corley DA, Quinn VP Douben CA, Zauber AG, Lee JK, 2hao WEK,
Marks AR, Schottinger JE, Ghai NR, Lee AT, Contreras R, Klabunde CN,
Quesenberry CP Levin TR, Mysliwiec PA. Fecal Immunochemnical Test Program
Performanmce Over 4 Rounds of Annual Screening: A Retrospective Cohort Study
Ann Intern Med. 2016: 164(⑦): 456-63. doi. 10.7326/M15-0983. PMID:26811150
61